Woippy, March 4th, 2024 – ABL Diagnostics (FR001400AHX6), a leading molecular diagnostics company, has announced today that its parent company, Advanced Biological Laboratory (ABL), has conducted three block transactions since August 2023, resulting in the sale of 59,651 shares of its common stock. These transactions have been reported to ONDE, the central information filing system of the Autorité…
No responses yet